RedHill Biopharma Gets Rights To Naloxegol, No Longer Core At AstraZeneca
Backed By Funds From HealthCare Royalty Partners
• By John Davis
Deal Snapshot: AstraZeneca has sublicensed global rights to its peripheral mu-opioid receptor antagonist to RedHill Biopharma, excluding Europe, Canada and Israel, with RedHill also separately receiving non-dilutive financing from HealthCare Royalty Partners.
GI diseases are a focus for RedHill Biopharma • Source: Shutterstock
Who: AstraZeneca/RedHill Biopharma
What: AstraZeneca has sublicensed global rights to Movantik, excluding Europe, Canada
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
